Traders should monitor upcoming FDA interactions on Varseta-M registrational pathway and clinical data readouts in 2026, particularly the CX-801/KEYTRUDA® combination data. While pipeline progress offers upside potential, the sharp revenue decline and reliance on future milestones increase risk; any delay could pressure valuation despite strong cash position.
CTMX drugs
CTMX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $6.75entry
- T+1 · 8mo ago −19.26%α −19.53% · $5.45
- T+5 · 8mo ago −33.93%α −31.88% · $4.46
- T+20 · 7mo ago −32.74%α −36.52% · $4.54
- T+60 · 5mo ago −56.44%α −66.93% · $2.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CytomX Therapeutics reported financial results for 2025, highlighted by a significant revenue decline to $76.2 million from $138.1 million in 2024, driven by the completion of collaboration milestones. However, the company announced positive Phase 1 data for its Varseta-M ADC in colorectal cancer and extended its cash runway into Q2 2027. Despite advancing its pipeline, including upcoming combination data for CX-801 with KEYTRUDA®, the sharp drop in revenue and net loss of $17.4 million weigh on near-term fundamentals.
Key Financial Metrics
Key Facts
- Revenue dropped to $76.2 million in 2025 from $138.1 million in 2024, primarily due to completion of performance obligations with Bristol Myers Squibb and reduced collaboration progress with Moderna, Astellas, and Regeneron.
- Net loss was $17.37 million in 2025 compared to net income of $31.87 million in 2024.
- Cash, cash equivalents, and investments totaled $137.1 million as of December 31, 2025, providing a cash runway into Q2 2027.
- Positive Phase 1 dose expansion data reported for Varseta-M in advanced colorectal cancer; FDA interactions planned for mid-2026 to align on registrational trial design.
- Phase 1 combination study of CX-801 with KEYTRUDA® in melanoma ongoing, with initial clinical data expected by end of 2026.
- Astellas terminated its preclinical collaboration with CytomX, effective Q2 2026.
Financial Impact
Revenue declined by 44.8% year-over-year, from $138.1M to $76.2M. Operating expenses decreased to $98.6M from $113.1M, but the company still posted a net loss of $17.37M. Cash balance increased to $137.1M due to prior funding and lower R&D spend.
Risk Factors
- Heavy dependence on clinical success of Varseta-M and CX-801 with no near-term commercial revenue.
- Revenue is largely collaboration-dependent and declined significantly after key milestones were completed.
- Forward-looking statements dominate the release; clinical timelines and regulatory alignment are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256146 |
Track record
10 reports on CTMX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
- Nov 5, 202611d ago Press Release Bearish 5/10 No price data
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
- Mar 17, 202634w ago Press Release Neutral 6/10 Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
- Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
- Mar 16, 202635w ago Press Release Mixed 6/10 Viewing Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
- Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers